Countstar


The clinical application of stem cell transplantation has been standardized

At the 7th national diabetic foot symposium held in Beijing on October 21th to October 22th, the expert consensus on the treatment of lower limb ischemia by autologous stem cell transplantation was published, organized and compiled by the stem cell engineering professional committee of Chinese medical association, which is the first standardized program guiding clinical stem cell transplantation treatment in China.

According to Consensus, indications for autologous stem cell transplantation include patients with chronic lower limb ischemic disease caused by various reasons, patients who are unable to receive arterial bypass or interventional therapy (balloon dilatation or stent intervention), and patients who fail conservative treatment such as drug therapy; Patients with tumors or significantly elevated levels of tumor markers in their blood within the past 5 years; Patients with severe cardiac, pulmonary, hepatic, and renal insufficiency, or with severe systemic infection, and patients with major artery occlusion such as main and iliac arteries, are contraindicated for this treatment. The consensus also made clear requirements on personnel qualification, perioperative management, stem cell preparation, methods of transplantation and postoperative evaluation of the treatment technology.

It is known that lower limb ischemia is a common clinical symptom, and atherosclerotic occlusion and diabetic foot are the main causes. Autologous stem cell transplantation (autologous stem cell transplantation) is a new therapy that can improve the symptoms of limb ischemia by injecting autologous stem cells locally in vitro and promoting the formation of new blood vessels at the ischemic site through its differentiation. It is reported that at present, autologous stem cell transplantation has been used to treat more than 8000 patients with lower limb ischemia in China, and the clinical effective rate is more than 80%.

The capital university of medical sciences institute of vascular surgery, deputy director of the valley, yongquan said, the countries of the ethical and moral issues and safety of stem cell transplantation is controversial, but the "consensus" is related to the autologous stem cells, there is no risk of immune rejection of allogeneic stem cells, embryonic stem cells of ethical questions, there is no heterogeneous serum levels of pollution and risk of genetic mutations, etc.

Wang zhonghao, a member of the Chinese academy of sciences and director of the institute of vascular surgery at capital medical university, said that autologous stem cell transplantation for chronic ischemic diseases of the lower limbs is a mature therapy confirmed by clinical experiments at home and abroad. In order to ensure clinical efficacy, the screening of indications and standardized operation are important preconditions.
Related News